LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 257

Search options

  1. Article ; Online: Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature.

    Ruffatti, Amelia / Tonello, Marta / Calligaro, Antonia / Del Ross, Teresa / Favaro, Maria / Zen, Margherita / Hoxha, Ariela / Alaibac, Mauro

    Clinical rheumatology

    2023  Volume 42, Issue 11, Page(s) 3007–3019

    Abstract: Obiectives: This study aims to prospectively evaluate the frequency and adverse consequences of diagnostic delay and misdiagnosis in a cohort of patients with thrombotic antiphospholipid syndrome (TAPS). In addition, a systematic review of the ... ...

    Abstract Obiectives: This study aims to prospectively evaluate the frequency and adverse consequences of diagnostic delay and misdiagnosis in a cohort of patients with thrombotic antiphospholipid syndrome (TAPS). In addition, a systematic review of the literature concerning the diagnostic delay and misdiagnosis of TAPS was carried out.
    Methods: Patient enrollment occurred between 1999 and 2022. The study group was formed by TAPS patients whose diagnosis was delayed and those who were misdiagnosed. The control group was made up of patients who were timely and correctly diagnosed with TAPS.
    Results: The literature review showed 42 misdiagnosed patients, 27 of them were in one retrospective cohort study and 15 in 13 case reports. One hundred sixty-one out of 189 patients (85.2%) received a timely, correct diagnosis of TAPS; 28 (14.8%) did not. The number of patients with diagnostic issues was significantly higher for the first period (1999-2010), and the number of patients with a correct diagnosis was significantly higher for the second one (2011-2022). When the clinical and laboratory characteristics of the patients with delayed diagnosis were compared with those with misdiagnosis, there was a significantly higher number of severe adverse consequences characterized by permanent disability or death in the latter group. The two most common types of misdiagnoses were systemic lupus erythematosus (6 cases, 46.1%) and cardiovascular diseases (4 cases, 30.8%).
    Conclusions: The study demonstrates that although knowledge about TAPS has improved over time, diagnostic delays and errors remains to be addressed as they are strongly associated to adverse consequences. Key Points •Although knowledge of thrombotic antiphospholipid syndrome has improved over time, it is still limited. •Diagnostic delay and misdiagnosis are still an important issue that remains to be addressed as they are strongly associated to adverse consequences. •The three more frequent misdiagnoses are multiple sclerosis, systemic lupus erythematosus and cardiovascular diseases.
    MeSH term(s) Humans ; Antiphospholipid Syndrome/diagnosis ; Antiphospholipid Syndrome/epidemiology ; Cardiovascular Diseases ; Cohort Studies ; Delayed Diagnosis ; Diagnostic Errors ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/diagnosis ; Lupus Erythematosus, Systemic/epidemiology ; Prevalence ; Retrospective Studies ; Thrombosis/diagnosis
    Language English
    Publishing date 2023-07-15
    Publishing country Germany
    Document type Review ; Journal Article
    ZDB-ID 604755-5
    ISSN 1434-9949 ; 0770-3198
    ISSN (online) 1434-9949
    ISSN 0770-3198
    DOI 10.1007/s10067-023-06699-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies.

    Ruffatti, Amelia / Tonello, Marta / Favaro, Maria / Del Ross, Teresa / Calligaro, Antonia / Ruffatti, Alessandra Teresa / Gervasi, Maria Teresa / Hoxha, Ariela

    Seminars in arthritis and rheumatism

    2020  Volume 51, Issue 1, Page(s) 28–35

    Abstract: Objective: The most efficacious strategy to manage pregnant patients with antiphospholipid syndrome (APS) refractory to conventional heparin/low-dose aspirin treatment or at high risk of adverse pregnancy outcomes has not been determined with any degree ...

    Abstract Objective: The most efficacious strategy to manage pregnant patients with antiphospholipid syndrome (APS) refractory to conventional heparin/low-dose aspirin treatment or at high risk of adverse pregnancy outcomes has not been determined with any degree of certainty. The study set out to evaluate the efficacy and safety of the second-line treatments most frequently used in addition to conventional therapy, and the data were analyzed to identify which is/are associated to the best pregnancy outcomes.
    Methods: A systematic review of the literature on studies concerning second-line treatments for refractory and/or high risk pregnant APS women published between February 2006 and February 2020 was conducted. The records were retrieved by searching Medline via Pubmed, the Web of Science platform, the Cochrane library database and clinicaltrials.gov.
    Results: Fourteen studies met the eligibility criteria of the review: six retrospective cohort studies, one case-control, one case-series and six case reports. The results of single treatment protocols based upon hydroxychloroquine (HCQ), low-dose steroids (LDS), intravenous immunoglobulins (IVIG), plasma exchange (PE) or pravastatin and of combination protocols based upon HCQ+LDS, IVIG+LDS, PE+LDS and PE+IVIG used during 313 pregnancies in 303 APS women were analyzed and compared. The second-line treatments produced 261/313 (83.4%) live births; severe pregnancy complications were registered in 75/313 (24%) pregnancies. Drug side-effects were observed in 3/313 (0.9%) pregnancies. Statistical analysis identified a significantly higher live birth rate and/or a significantly lower number of severe complications in the pregnancies treated with IVIG, HCQ, pravastatin, PE+IVIG and PE+LDS.
    Conclusion: Our results suggest using low-dose IVIG (< 2 g/Kg/month) or HCQ 400 mg/day starting before pregnancy in women with APS refractory to conventional therapy, while high-dose IVIG (2 g/Kg/month) associated with PE or alone in those with high risk±refractory APS.
    MeSH term(s) Antiphospholipid Syndrome/complications ; Antiphospholipid Syndrome/drug therapy ; Aspirin/therapeutic use ; Female ; Humans ; Pregnancy ; Pregnancy Complications/drug therapy ; Pregnancy Outcome ; Retrospective Studies
    Chemical Substances Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2020-12-17
    Publishing country United States
    Document type Journal Article ; Review ; Systematic Review
    ZDB-ID 120247-9
    ISSN 1532-866X ; 0049-0172
    ISSN (online) 1532-866X
    ISSN 0049-0172
    DOI 10.1016/j.semarthrit.2020.10.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study.

    Hoxha, Ariela / Favaro, Maria / Calligaro, Antonia / Del Ross, Teresa / Ruffatti, Alessandra Teresa / Infantolino, Chiara / Tonello, Marta / Mattia, Elena / Ruffatti, Amelia

    Thrombosis and haemostasis

    2019  Volume 120, Issue 1, Page(s) 36–43

    Abstract: The current study evaluates the efficacy and safety of different treatment strategies for pregnant patients with antiphospholipid syndrome. One hundred twenty-seven consecutive pregnancies were assessed; 87 (68.5%) with a history of pregnancy morbidity ... ...

    Abstract The current study evaluates the efficacy and safety of different treatment strategies for pregnant patients with antiphospholipid syndrome. One hundred twenty-seven consecutive pregnancies were assessed; 87 (68.5%) with a history of pregnancy morbidity alone were treated with prophylactic low molecular weight heparin (LMWH) + low-dose aspirin (LDA, 100 mg) (group I) and 40 (31.5%) with a history of thrombosis and/or severe pregnancy complications with therapeutic LMWH + LDA (group II). LMWH doses were increased throughout the pregnancies depending on the patients' weight gain, and treatment was switched to a more intensive one at the first sign of maternal/fetal complications. The study's primary outcome was live births. There were no significant differences in live birth rate between group I (95.4%) and group II (87.5%). Even fetal complication rate was similar in the two groups; group II nevertheless had a higher prevalence of maternal and neonatal complications (
    MeSH term(s) Adult ; Antibodies, Antiphospholipid/blood ; Antiphospholipid Syndrome/drug therapy ; Aspirin/therapeutic use ; Cohort Studies ; Drug Dosage Calculations ; Drug Therapy, Combination ; Female ; Heparin, Low-Molecular-Weight/therapeutic use ; Humans ; Immunoglobulins, Intravenous/therapeutic use ; Middle Aged ; Plasmapheresis/methods ; Pregnancy ; Pregnancy Complications/drug therapy ; Pregnancy Outcome ; Pregnancy Rate ; Thrombosis/drug therapy
    Chemical Substances Antibodies, Antiphospholipid ; Heparin, Low-Molecular-Weight ; Immunoglobulins, Intravenous ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2019-10-21
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 518294-3
    ISSN 2567-689X ; 0340-6245
    ISSN (online) 2567-689X
    ISSN 0340-6245
    DOI 10.1055/s-0039-1697665
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation.

    Zen, Margherita / Tonello, Marta / Favaro, Maria / Del Ross, Teresa / Calligaro, Antonia / Giollo, Alessandro / Vesentini, Filippo / Gennaio, Ilenia Anna / Arru, Federico / Ruffatti, Amelia / Doria, Andrea

    Rheumatology (Oxford, England)

    2023  

    Abstract: Objectives: Complement activation has been advocated as one mechanism by which antiphospholipid antibodies (aPLs) can induce thrombosis. In patients with catastrophic aPL syndrome or re-thrombosis, enhanced complement activation was shown, even in ... ...

    Abstract Objectives: Complement activation has been advocated as one mechanism by which antiphospholipid antibodies (aPLs) can induce thrombosis. In patients with catastrophic aPL syndrome or re-thrombosis, enhanced complement activation was shown, even in quiescent phase of the disease. We aimed to assess complement activation and to investigate its association to clinical variables in aPL positive patients with a favorable disease course.
    Methods: Subjects with at least two consecutive positive aPL antibody results obtained ≥12 weeks apart were enrolled. They were subjects without history of thrombosis or pregnancy morbidity (aPL carriers), patients with pregnancy morbidity alone (OAPS), and/or with arterial, venous, or small-vessel thrombosis (TAPS); all patients should have been free of symptoms for ≥2 years. Patients affected with systemic autoimmune diseases were excluded. Healthy age and sex-matched subjects were included as controls. Plasma C5a and C5b-9 levels were assessed by commercially available ELISA assays. Non-parametric Mann-Whitney test and Spearman's correlation were applied.
    Results: Thirty-seven OAPS, 38 TAPS, 42 aPL carriers, and 30 healthy subjects were enrolled. Median C5a and C5b-9 levels were significantly higher in quiescent aPL positive patients (OAPS, TAPS, aPL carriers) compared with controls: C5a ng/ml 10.61 (IQR 6.87-15.46) vs 4.06 (2.66-7.35), p< 0.001; C5b-9 ng/ml 283.95 (175.8-439.40) vs 165.90 (124.23-236.8), p< 0.001. Similar C5a and C5b-9 levels were observed in OAPS and TAPS patients and aPL carriers. A positive correlation between C5b-9 median levels and the number of aPL positive tests was found (p= 0.002).
    Conclusions: The persistence of aPL antibodies is associated to a persistent subclinical activation of the complement cascade.
    Language English
    Publishing date 2023-09-29
    Publishing country England
    Document type Journal Article
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/kead517
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Detection of lupus anticoagulant in the era of direct oral anticoagulants.

    Hoxha, Ariela / Banzato, Alessandra / Ruffatti, Amelia / Pengo, Vittorio

    Autoimmunity reviews

    2017  Volume 16, Issue 2, Page(s) 173–178

    Abstract: Lupus anticoagulant (LAC) is an in vitro phenomenon determining a phospholipid-dependent elongation of clotting times. The presence of LAC associated with anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies is strongly associated ... ...

    Abstract Lupus anticoagulant (LAC) is an in vitro phenomenon determining a phospholipid-dependent elongation of clotting times. The presence of LAC associated with anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies is strongly associated with thrombosis and pregnancy morbidity. Direct oral anticoagulants (DOACs) targeting thrombin and factor Xa are currently widely use to prevent and treat venous and arterial thromboembolism. Some concern has, however, been expressed about the possibility of false laboratory results during LAC assessment in patients taking these drugs. Several in vitro studies, spiking DOACs into normal plasma as well as ex vivo at peak levels in treated patients, led in false-positive LAC. The dilute Russell Viper Venom time is the assay that is most influenced by rivaroxaban, edoxaban, dabigatran and less by apixaban. Both screening and confirmatory tests have resulted equally prolonged for activated partial thromboplastin time and have not led to false-positive results, but this may depend on the type of reagent used for the test. Taipan/Ecarin snake venoms ratios, has been recommend by some investigators as they do not seem to be affected by rivaroxaban or edoxaban, but these tests are neither standardized nor generally available in clinical practice. In conclusion, for the time being it does not seem advisable to carry out LAC testing during anti-factor Xa and anti-factor IIa treatment because of the risk of false-positive results. Whenever needed in deciding the suspension of DOACs or in case of recurrent thrombosis, LAC determination should be carried out at trough better if DOAC concentration is known.
    MeSH term(s) Administration, Oral ; Anticoagulants/therapeutic use ; Antiphospholipid Syndrome/drug therapy ; Antiphospholipid Syndrome/immunology ; Dabigatran/administration & dosage ; Dabigatran/therapeutic use ; Humans ; Lupus Coagulation Inhibitor/administration & dosage ; Lupus Coagulation Inhibitor/therapeutic use ; Rivaroxaban/administration & dosage ; Rivaroxaban/therapeutic use
    Chemical Substances Anticoagulants ; Lupus Coagulation Inhibitor ; Rivaroxaban (9NDF7JZ4M3) ; Dabigatran (I0VM4M70GC)
    Language English
    Publishing date 2017-02
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2144145-5
    ISSN 1873-0183 ; 1568-9972
    ISSN (online) 1873-0183
    ISSN 1568-9972
    DOI 10.1016/j.autrev.2016.12.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Management of pregnant women with antiphospholipid antibodies.

    Ruffatti, Amelia / Favaro, Maria / Calligaro, Antonia / Zambon, Alessandra / Del Ross, Teresa

    Expert review of clinical immunology

    2019  Volume 15, Issue 4, Page(s) 347–358

    Abstract: Introduction: Important advancements in pregnancy outcome have been reported in women with antiphospholipid antibodies (aPL), despite the fact that the treatment of aPL related pregnancy morbidity is not guided by consistent findings from well-designed ... ...

    Abstract Introduction: Important advancements in pregnancy outcome have been reported in women with antiphospholipid antibodies (aPL), despite the fact that the treatment of aPL related pregnancy morbidity is not guided by consistent findings from well-designed trials. Areas covered: The current study draws a picture of the studies in the literature by performing a Medline search of relevant English language articles and reports our experience in managing different subsets of obstetric antiphospholipid syndrome (APS), defined on the basis of their clinical and laboratory characteristics. The management of pregnant women with non-criteria APS manifestations and that of aPL carriers during their first pregnancy is also examined. Expert commentary: A heparin/aspirin combination constitutes conventional treatment for APS affected pregnant women. As this strategy fails in approximately 20-30% of cases, uncovering other options for women refractory to conventional treatment or at high risk of pregnancy complications has become an urgent undertaking. Some attempts have been made to prescribe additional treatments in the effort to improve live birth rates and/or reduce pregnancy complications, which often occur even in patients treated conventionally. The evidence from some studies and an individual risk/benefit assessment should instead guide treatment decisions for pregnant patients with non-criteria APS manifestations and aPL carriers.
    MeSH term(s) Antibodies, Antiphospholipid/metabolism ; Antiphospholipid Syndrome/diagnosis ; Antiphospholipid Syndrome/therapy ; Aspirin/therapeutic use ; Drug Combinations ; Female ; Heparin/therapeutic use ; Humans ; Pregnancy ; Risk Assessment ; Risk Factors
    Chemical Substances Antibodies, Antiphospholipid ; Drug Combinations ; Heparin (9005-49-6) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2019-01-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2019.1565995
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Collaboration Between a School Nurse Task Force and the Local Health Department in Illinois: Development of a COVID-19 Toolkit.

    Kunz, Donna J / Manno, Martha S / Ruffatti, Dawn M / Blohm, Suzanne L / Wuerger, Amelia A / Keegan, Amanda J / Karras, Susan L

    NASN school nurse (Print)

    2021  Volume 37, Issue 1, Page(s) 36–40

    Abstract: Multidisciplinary collaboration for healthy student outcomes is not a new concept for school nurses nor is working with public health officials in promoting school-community initiatives. The SARS-CoV-2 (COVID-19; severe acute respiratory syndrome ... ...

    Abstract Multidisciplinary collaboration for healthy student outcomes is not a new concept for school nurses nor is working with public health officials in promoting school-community initiatives. The SARS-CoV-2 (COVID-19; severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019) virus further highlighted the need to work together to promote best practice strategies to arm the community with information and guidance to prevent illness. The McHenry County Health Department recognized the expertise school nurses have in school health and formed a voluntary School Nurse Task Force. This collaboration worked to implement requirements for operating a school during a pandemic. The task force adapted those concepts into a toolkit to assist schools to meet health requirements throughout the most significant pandemic in over 100 years.
    MeSH term(s) COVID-19 ; Humans ; Pandemics ; SARS-CoV-2 ; School Nursing ; Schools
    Language English
    Publishing date 2021-05-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2445634-2
    ISSN 1942-6038 ; 1942-602X
    ISSN (online) 1942-6038
    ISSN 1942-602X
    DOI 10.1177/1942602X211015298
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Are biological drugs safe in pregnancy?

    Calligaro, A / Hoxha, A / Ruffatti, A / Punzi, L

    Reumatismo

    2015  Volume 66, Issue 4, Page(s) 304–317

    Abstract: The introduction of biological therapies has significantly improved the outcome of inflammatory rheumatic diseases. As most of these diseases affect women and men in childbearing age, some concerns have been voiced as to the safety of these drugs in ... ...

    Abstract The introduction of biological therapies has significantly improved the outcome of inflammatory rheumatic diseases. As most of these diseases affect women and men in childbearing age, some concerns have been voiced as to the safety of these drugs in relation to reproduction and pregnancy. Data from many hundreds of pregnancies in patients affected by inflammatory bowel disease and inflammatory arthritis have suggested that exposure to anti-TNF therapies at conception and/or during pregnancy is not associated with adverse pregnancy outcomes or any increase in congenital abnormalities. However, the exposure to anti-TNFα agents, particularly to monoclonal antibodies, in late pregnancy is associated with high drug levels in the newborn and their long-term effects on children remain unknown. Therefore, limiting the use of anti-TNFα to the first 30 weeks of pregnancy is recommended to reduce fetal exposure. Live-virus vaccines should be given only when levels of anti-TNFα drugs are undetectable in the serum of infants. Studies suggest that many of these drugs do enter breast milk in small amounts, but the extent to which the infant absorbs them is less clear. Limited reports have not suggested adverse pregnancy outcomes in women whose partners were exposed to anti-TNF therapies at the time of conception. Pregnancy data for rituximab, abatacept, anakinra, tocilizumab and belimumab are limited and their use in pregnancy cannot currently be recommended.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antirheumatic Agents/therapeutic use ; Evidence-Based Medicine ; Female ; Humans ; Immunologic Factors/therapeutic use ; Infant, Newborn ; Inflammatory Bowel Diseases/drug therapy ; Pregnancy ; Pregnancy Complications/drug therapy ; Rheumatic Diseases/drug therapy ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    Chemical Substances Antibodies, Monoclonal ; Antirheumatic Agents ; Immunologic Factors ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2015-03-31
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 414816-2
    ISSN 2240-2683 ; 0048-7449
    ISSN (online) 2240-2683
    ISSN 0048-7449
    DOI 10.4081/reumatismo.2014.798
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets.

    Ruffatti, Amelia / Tonello, Marta / Calligaro, Antonia / Del Ross, Teresa / Favaro, Maria / Zen, Margherita / Carletto, Antonio / Lotti, Virginia / Bertoldo, Eugenia / Tedesco, Francesco / Hoxha, Ariela / Biasi, Domenico

    Clinical and experimental rheumatology

    2022  Volume 40, Issue 11, Page(s) 2088–2096

    Abstract: Objectives: High plasma C5a and C5b-9 levels are considered a clear sign of complement activation. We aimed to evaluate the clinical significance of these two complement activation products during quiescent phases of thrombotic antiphospholipid syndrome ...

    Abstract Objectives: High plasma C5a and C5b-9 levels are considered a clear sign of complement activation. We aimed to evaluate the clinical significance of these two complement activation products during quiescent phases of thrombotic antiphospholipid syndrome (APS) by comparing their plasma levels in the different clinical subsets and relating them to the clinical characteristics and antiphospholipid antibody profile of the patients.
    Methods: The three patient subsets studied were: i) thrombotic patients responsive to anti-vitamin K therapy (TAPS); ii) patients with refractory to vitamin K antagonists recurrent thrombosis (RAPS); iii) patients diagnosed with catastrophic APS (CAPS). Plasma C5a and C5b-9 levels were assessed using commercial ELISA assays.
    Resulyts: Sixty-two quiescent APS patients were recruited: 40 were affected by TAPS, 13 by RAPS and 9 by CAPS. Data analysis showed that the TAPS patients had significantly lower levels of both complement activation products with respect to the RAPS and CAPS patients. In addition, C5a and/or C5b-9 significantly prevailed in the patients with small-vessel thrombosis, just as C5b-9 did in the triple antiphospholipid antibody positive patients. The ROC curve showed that the best cut-offs for C5a and C5b-9 levels had a higher sensitivity, specificity and likelihood ratio in the CAPS and RAPS groups than they did in the TAPS subset.
    Conclusions: These results suggest that the persistence of high plasma C5b-9 and C5a levels during quiescent phases identifies APS patients with more severe disease who may develop rethrombosis and benefit from complement inhibition treatment during an acute disease phase.
    MeSH term(s) Humans ; Antiphospholipid Syndrome/complications ; Antiphospholipid Syndrome/diagnosis ; Antiphospholipid Syndrome/drug therapy ; Complement Membrane Attack Complex ; Antibodies, Antiphospholipid ; Anticoagulants/therapeutic use ; Thrombosis/drug therapy ; Thrombosis/etiology
    Chemical Substances Complement Membrane Attack Complex ; Antibodies, Antiphospholipid ; Anticoagulants
    Language English
    Publishing date 2022-03-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 605886-3
    ISSN 1593-098X ; 0392-856X
    ISSN (online) 1593-098X
    ISSN 0392-856X
    DOI 10.55563/clinexprheumatol/7cinzu
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study.

    Ruffatti, Amelia / Cerutti, Alessia / Tonello, Marta / Favaro, Maria / Del Ross, Teresa / Calligaro, Antonia / Grava, Chiara / Zen, Margherita / Hoxha, Ariela / Di Salvo, Giovanni

    Journal of perinatology : official journal of the California Perinatal Association

    2022  Volume 42, Issue 9, Page(s) 1161–1168

    Abstract: Objective: The short and long-term outcomes of children with anti-Ro/La-related congenital heart block treated with a combined maternal-neonatal therapy protocol were compared with those of controls treated with other therapies.: Study design: ... ...

    Abstract Objective: The short and long-term outcomes of children with anti-Ro/La-related congenital heart block treated with a combined maternal-neonatal therapy protocol were compared with those of controls treated with other therapies.
    Study design: Sixteen mothers were treated during pregnancy with a therapy consisting of daily oral fluorinated steroids, weekly plasma exchange and fortnightly intravenous immunoglobulins and their neonates with intravenous immunoglobulins (study group); 19 mothers were treated with fluorinated steroids alone or associated to intravenous immunoglobulins or plasma exchange (control group).
    Result: The combined-therapy children showed a significantly lower progression rate from 2nd to 3rd degree block at birth, a significant increase in heart rate at birth and a significantly lower number of pacemaker implants during post-natal follow-up with respect to those treated with the other therapies.
    Conclusion: The combined therapy produced better short and long term outcomes with respect to the other therapies studied.
    MeSH term(s) Betamethasone ; Child ; Female ; Heart Block/congenital ; Heart Block/therapy ; Humans ; Immunoglobulins, Intravenous/therapeutic use ; Infant, Newborn ; Pregnancy ; Steroids, Fluorinated
    Chemical Substances Immunoglobulins, Intravenous ; Steroids, Fluorinated ; Betamethasone (9842X06Q6M)
    Language English
    Publishing date 2022-06-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 645021-0
    ISSN 1476-5543 ; 0743-8346
    ISSN (online) 1476-5543
    ISSN 0743-8346
    DOI 10.1038/s41372-022-01431-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top